Response to azacitidine according to IWG 2006 criteria in the intent-to-treat cohort (n = 282)
| IWG 2006 response . | Response achievement . | Duration (mo) . | ||
|---|---|---|---|---|
| n . | % . | Median . | Range . | |
| Complete response (CR) | 38 | 14 | 10.4 | 1-24+ |
| Partial response (PR) | 9 | 3 | 9.8 | 1-13 |
| Marrow CR (mCR) | 32 | 11 | 8.0 | 2-38+ |
| Stable disease with hematological improvement | 43 | 15 | 7.9 | 2-28+ |
| Stable disease without hematological improvement | 61 | 22 | ||
| Progressive disease | 52 | 18 | ||
| Failure to achieve 4 cycles of AZA | 47 | 17 | ||
| Overall response rate (CR + PR + mCR + SD with HI) | 122 | 43 | 9.5 | 1-38+ |
| IWG 2006 response . | Response achievement . | Duration (mo) . | ||
|---|---|---|---|---|
| n . | % . | Median . | Range . | |
| Complete response (CR) | 38 | 14 | 10.4 | 1-24+ |
| Partial response (PR) | 9 | 3 | 9.8 | 1-13 |
| Marrow CR (mCR) | 32 | 11 | 8.0 | 2-38+ |
| Stable disease with hematological improvement | 43 | 15 | 7.9 | 2-28+ |
| Stable disease without hematological improvement | 61 | 22 | ||
| Progressive disease | 52 | 18 | ||
| Failure to achieve 4 cycles of AZA | 47 | 17 | ||
| Overall response rate (CR + PR + mCR + SD with HI) | 122 | 43 | 9.5 | 1-38+ |